menu search

TScan Therapeutics Announces Pricing of $140 Million Public Offering

TScan Therapeutics Announces Pricing of $140 Million Public Offering
WALTHAM, Mass., May 26, 2023 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 22,989,474 shares of its voting common stock at […] The post TScan Therapeutics Announces Pricing of $140 Million Public Offering appeared first on ForexTV... Read More
Posted: May 26 2023, 04:37
Author Name: forextv
Views: 110577

Search within

Pages Search Results: